1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H

Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H

HHKEX:8329
0.09
HKD
+0.00
(-3.19%)
239.95MMarket Cap
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H
HKEX:8329
(Hong Kong Exchange)

Recent

price

0.09

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.04
0.28
0.32
0.36
0.39
0.43
0.45
0.47
0.52
0.64
0.61
0.5
0.59
0.63
0.62
0.58
- -
Revenue per Share
-0.03
0.01
0.01
0.02
0.02
0.01
0.04
0.03
0.03
0.04
0.02
0.02
0.03
0.01
0.01
-0.02
- -
Basic EPS, GAAP
-0.01
-0.08
- -
-0.02
0.01
0.02
0.04
0.02
- -
0.02
0.03
-0.05
0.02
0.02
- -
0.07
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.15
- -
Dividend per Share
0.23
0.25
0.26
0.28
0.3
0.32
0.36
0.39
0.42
0.45
0.47
0.49
0.53
0.54
0.56
0.39
0.56
Book Value per Share
0.15
0.17
0.18
0.2
0.22
0.25
0.29
0.32
0.32
0.39
0.42
0.37
0.4
0.42
0.44
0.31
0.45
Tangible Book Value per Share
1,004
1,678
1,678
1,678
1,678
1,678
1,678
1,678
1,678
1,678
1,678
1,678
1,678
1,678
1,678
1,678
1,678
Basic Weighted Avg Shares
38
475
530
612
648
721
759
790
867
1,081
1,031
839
987
1,065
1,042
972
- -
Sales/Revenue/Turnover
-51.39
9.23
8.49
7.83
10.43
7
11.9
8.41
6.88
6.69
4.16
3.13
7.49
1.48
2.7
-4.34
- -
Operating Margin (%)
9
23
20
22
23
23
20
19
20
24
26
30
36
34
35
33
- -
Depreciation Expense
-30
22
24
36
33
21
63
50
48
60
37
36
54
24
25
-41
- -
Net Income, GAAP
- -
43.57
11.14
- -
26.39
31.97
19.69
21.19
24.51
19.55
22.84
12.28
22.41
52.64
53.57
- -
- -
Effective Tax Rate (%)
-78.69
4.57
4.58
5.86
5.12
2.92
8.26
6.36
5.55
5.53
3.55
4.29
5.51
2.27
2.4
-4.19
- -
Profit Margin (%)
16
185
173
199
181
297
366
471
512
562
597
404
482
554
469
328
600
Working Capital
62
- -
- -
- -
- -
- -
- -
- -
- -
3
- -
1
4
4
5
3
8
LT Debt
456
486
518
561
600
632
700
750
799
860
896
944
1,005
1,016
1,026
704
1,057
Total Equity
- -
4.12
7.08
- -
7.6
5.18
9.64
7.15
6.47
7.46
4.33
3.95
6.54
1.58
1.47
- -
- -
Return on Invested Capital (%)
- -
3.67
3.13
- -
4.39
2.41
7.19
5.96
5.82
6.68
3.88
4.26
4.68
3.3
3.45
- -
- -
Return on Capital (%)
-14.19
5.37
5.67
7.81
6.73
4.02
11.03
8.04
7.14
8.21
4.72
4.43
6.34
2.69
2.72
-5.15
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Sep'23
Dec'23
Jun'24
ST Debt
- -
86
86
LT Borrowings
- -
2
6
LT Finance Leases
- -
1
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,678
1,678
1,678
Market Capitalization
257
250
223

Working Capital

CNY

•

in mil. unless spec.
Sep'23
Dec'23
Jun'24
Total Current Assets
- -
921
931
Cash, Cash Equivalents & STI
- -
382
392
Accounts Receivable, Net
- -
174
179
Inventories
- -
205
201
Total Current Liabilities
- -
366
331
Payables & Accruals
- -
- -
- -
ST Debt
- -
86
86
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
1.88%
-3.49%
-31.39%
Free Cash Flow
397.24%
1,015.23%
5,574.57%
Net Income, GAAP
-10.63%
-53.07%
-262.86%
Sales/Revenue/Turnover
3.71%
-0.4%
-6.69%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1,042
2025
- -
- -
972
2026
- -
- -
- -

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.01
2025
- -
- -
-0.02
2026
- -
- -
- -

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
0.15
2026
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK) engages in the research, development, manufacturing, and sale of medicines and medical devices in China. The company produces pharmaceuticals targeting oncology, cardiovascular, respiratory, digestive systems, and mental disorders; it also handles sales and distribution of medicines, healthcare food products, and medical devices through two main segments: manufacturing and selling of medicines/medical devices, and sales/distribution of medicines, healthcare products, and medical devices. Incorporated in 2002 and headquartered in Shenzhen with a listed office in Quarry Bay, Hong Kong, it primarily serves the domestic Chinese market and operates as a subsidiary of Shenzhen Neptunus Bio-engineering Company Limited. Recent developments include the announcement of a New Neptunus Group Sales Framework Agreement in late 2025 for ongoing transactions with related parties, alongside termination of a controlling shareholder's shareholding change in 2024 and release of 2024 annual results showing revenue of approximately HK$1.09 billion. The company maintains about 1,470 employees and focuses on biological technology R&D amid subdued growth and stock performance fluctuations in the pharmaceuticals sector.